JNPMEDI, an AI platform-based clinical trial consulting firm, announced on the 6th that it is enhancing clinical trial efficiency through its proprietary clinical operation and data management solution, 'Maven Clinical Cloud.'
The company focuses on automating the entire clinical trial process by leveraging AI that interprets clinical trial protocols. This involves research centered on AI technology capable of structuring and analyzing unstructured natural language data. It also includes automatically generating Case Report Forms (eCRF) based on protocols and creating rules for efficient, accurate data collection.
AI is gaining attention as a solution to simultaneously address the dual challenges of reducing clinical trial costs and accelerating timelines. In practice, AI has been shown to shorten clinical trial start-up times by 15-20% and reduce overall clinical trial duration by 15-30%.
JNPMEDI's AI-driven technology is also broadening its application in regulatory compliance and data standardization.
To support companies entering the U.S. market, the company launched 'FDA Expert Solution' in July of last year. This comprehensive consulting service aids in obtaining Investigational New Drug (IND) approvals and New Drug Application (NDA) approvals from the U.S. Food and Drug Administration (FDA).
The FDA Expert Solution supports the entire communication process with the FDA. It uses AI technology to facilitate a regulation-friendly data structure and workflow, such as interpreting conditions and variables within protocols to extract key elements needed for eCRF design.
The company also continuously researches features that automatically suggest and apply data quality control rules for precise review and validation of collected data.
'Maven Converter,' which incorporates AI mapping technology to automatically convert data into FDA-required formats, helps reduce time and costs while increasing accuracy in data standardization.
Notably, JNPMEDI's AI solutions are built on a stable cloud infrastructure. The company is designing and validating a cloud-based system optimized for the healthcare and life sciences sectors, with technical support from Amazon Web Services (AWS).
YoungYong Park, CTO of JNPMEDI, stated, "AI will play a pivotal role not only in reducing clinical trial costs and accelerating speed but also in promoting the development of patient-specific treatments and addressing unmet medical needs."
| By Lee Mi-sun, Digital Times ([email protected])
📌 Original article: https://n.news.naver.com/mnews/article/029/0002966243?sid=105
JNPMEDI, an AI platform-based clinical trial consulting firm, announced on the 6th that it is enhancing clinical trial efficiency through its proprietary clinical operation and data management solution, 'Maven Clinical Cloud.'
The company focuses on automating the entire clinical trial process by leveraging AI that interprets clinical trial protocols. This involves research centered on AI technology capable of structuring and analyzing unstructured natural language data. It also includes automatically generating Case Report Forms (eCRF) based on protocols and creating rules for efficient, accurate data collection.
AI is gaining attention as a solution to simultaneously address the dual challenges of reducing clinical trial costs and accelerating timelines. In practice, AI has been shown to shorten clinical trial start-up times by 15-20% and reduce overall clinical trial duration by 15-30%.
JNPMEDI's AI-driven technology is also broadening its application in regulatory compliance and data standardization.
To support companies entering the U.S. market, the company launched 'FDA Expert Solution' in July of last year. This comprehensive consulting service aids in obtaining Investigational New Drug (IND) approvals and New Drug Application (NDA) approvals from the U.S. Food and Drug Administration (FDA).
The FDA Expert Solution supports the entire communication process with the FDA. It uses AI technology to facilitate a regulation-friendly data structure and workflow, such as interpreting conditions and variables within protocols to extract key elements needed for eCRF design.
The company also continuously researches features that automatically suggest and apply data quality control rules for precise review and validation of collected data.
'Maven Converter,' which incorporates AI mapping technology to automatically convert data into FDA-required formats, helps reduce time and costs while increasing accuracy in data standardization.
Notably, JNPMEDI's AI solutions are built on a stable cloud infrastructure. The company is designing and validating a cloud-based system optimized for the healthcare and life sciences sectors, with technical support from Amazon Web Services (AWS).
YoungYong Park, CTO of JNPMEDI, stated, "AI will play a pivotal role not only in reducing clinical trial costs and accelerating speed but also in promoting the development of patient-specific treatments and addressing unmet medical needs."
| By Lee Mi-sun, Digital Times ([email protected])
📌 Original article: https://n.news.naver.com/mnews/article/029/0002966243?sid=105